

- Sub E 1
- (a) amino acids +23 to +371 of SEQ ID NO:2;
 - (b) amino acids +2 to +371 of SEQ ID NO:2;
 - (c) amino acids +1 to +371 of SEQ ID NO:2;
 - (d) the amino acid sequence of the mature polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 209691 or 209641; and
 - (e) the amino acid sequence of the full length polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 209691 or 209641;

wherein percent identity is calculated using FASTDB with the parameters set such that percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acids in the reference amino acid sequence are allowed.

Sub D 25. ~~26. An isolated polynucleotide complementary to the polynucleotide of claim~~

27. The isolated polynucleotide of claim 25 further comprising a heterologous polynucleotide.

28. A vector comprising the polynucleotide of claim 25.

29. A method of producing a vector comprising inserting the isolated polynucleotide of claim 25 into a vector.

a 30. A host cell comprising the vector of claim 28.

Sub C 31. A host cell comprising the isolated polynucleotide of 25 operably associated with a heterologous regulatory sequence.

32. A method of producing a polypeptide comprising:

(a) culturing the host cell of claim 31 under conditions such that the polypeptide is expressed; and

(b) recovering said polypeptide.

33. A composition comprising the isolated polynucleotide of claim 25.

34. An isolated polynucleotide comprising a nucleic acid encoding an amino acid sequence, wherein, except for one to thirty amino acid substitutions, said amino acid sequence is identical to a polypeptide sequence selected from the group consisting of:

- Sub 2*
- (a) amino acids +23 to +371 of SEQ ID NO:2;
 - (b) amino acids +2 to +371 of SEQ ID NO:2;
 - (c) amino acids +1 to +371 of SEQ ID NO:2;
 - (d) the amino acid sequence of the mature polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 209691 or 209641; and
 - (e) the amino acid sequence of the full length polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 209691 or 209641.

35. An isolated polynucleotide comprising a first nucleic acid 95% or more identical to a reference nucleic acid encoding an amino acid sequence selected from the group consisting of:

- a*
- (a) amino acids +23 to +371 of SEQ ID NO:2;
 - (b) amino acids +2 to +371 of SEQ ID NO:2;
 - (c) amino acids +1 to +371 of SEQ ID NO:2;
 - (d) the amino acid sequence of the mature polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 209691 or 209641; and
 - (e) the amino acid sequence of the complete polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 209691 or 209641;

wherein percent identity is calculated using FASTDB with the parameters set such that percentage of identity is calculated over the full length of the reference nucleic acid and that gaps in homology of up to 5% of the total number of nucleotides in the reference nucleic acid are allowed.

Sub 1

36. An isolated polynucleotide comprising a nucleic acid that hybridizes to a polynucleotide consisting of SEQ ID NO:1, the complement thereof, or the cDNA contained in ATCC Deposit No. 209691 or 209641 under hybridization conditions comprising hybridization in a wash buffer consisting of 0.1XSSC at 65°C.

sub C2

37. An isolated polynucleotide comprising a nucleic acid selected from the group consisting of:

- (a) a nucleic acid encoding a polypeptide comprising amino acid residues m-371 of SEQ ID NO:2, where m is an integer in the range of +2 to +370;
- (b) a nucleic acid encoding a polypeptide comprising amino acid residues 1-n of SEQ ID NO:2, where n is an integer in the range of +2 to +371; and
- (c) a nucleic acid encoding a polypeptide comprising amino acid residues m-n of SEQ ID NO:2, where m is an integer in the range of +2 to +370 and n is an integer in the range of +2 to +371.

38. The isolated polynucleotide of claim 37, wherein said nucleic acid is (c).

39. The isolated polynucleotide of claim 38, wherein said nucleic acid encodes a polypeptide selected from the group consisting of:

- (a) a polypeptide comprising amino acids +198 to +204 of SEQ ID NO:2;
 - (b) a polypeptide comprising amino acids +261 to +268 of SEQ ID NO:2;
 - (c) a polypeptide comprising amino acids +23 to +225 of SEQ ID NO:2;
 - (d) a polypeptide comprising amino acids +1 to +231 of SEQ ID NO:2;
- and
- (e) a polypeptide comprising amino acids +226 to +260 of SEQ ID NO:2.

40. The isolated polynucleotide of claim 38, wherein said nucleic acid encodes a polypeptide selected from the group consisting of:

- (a) a polypeptide comprising amino acids +22 to +29 of SEQ ID NO:2;
- (b) a polypeptide comprising amino acids +48 to +56 of SEQ ID NO:2;
- (c) a polypeptide comprising amino acids +62 to +73 of SEQ ID NO:2;
- (d) a polypeptide comprising amino acids +78 to +85 of SEQ ID NO:2;
- (e) a polypeptide comprising amino acids +88 to +95 of SEQ ID NO:2;
- (f) a polypeptide comprising amino acids +99 to +105 of SEQ ID NO:2;
- (g) a polypeptide comprising amino acids +118 to +126 of SEQ ID NO:2;
- (h) a polypeptide comprising amino acids +139 to +146 of SEQ ID NO:2;

- (i) a polypeptide comprising amino acids +151 to +169 of SEQ ID NO:2;
 - (j) a polypeptide comprising amino acids +188 to +206 of SEQ ID NO:2;
 - (k) a polypeptide comprising amino acids +208 to +231 of SEQ ID NO:2;
 - (l) a polypeptide comprising amino acids +264 to +271 of SEQ ID NO:2;
 - (m) a polypeptide comprising amino acids +286 to +293 of SEQ ID NO:2;
 - (n) a polypeptide comprising amino acids +300 to +313 of SEQ ID NO:2;
 - (o) a polypeptide comprising amino acids +317 to +342 of SEQ ID NO:2;
 - (p) a polypeptide comprising amino acids +347 to +353 of SEQ ID NO:2;
- and
- (q) a polypeptide comprising amino acids +363 to +369 of SEQ ID NO:2.

Surge 41. An isolated polynucleotide comprising 150 contiguous nucleotides of SEQ ID NO:1 or the complement thereof.

42. An isolated polynucleotide comprising a nucleic acid encoding at least 30 contiguous amino acids of SEQ ID NO:2.

a' 43. The isolated polynucleotide of claim 42, wherein said nucleic acid encodes at least 50 contiguous amino acids of SEQ ID NO:2.

Surge 44. An isolated polynucleotide complementary to the polynucleotide of claim 42.

45. The isolated polynucleotide of claim 42 further comprising a heterologous polynucleotide.

46. A vector comprising the polynucleotide of claim 42.

47. A method of producing a vector comprising inserting the isolated polynucleotide of claim 42 into a vector.

48. A host cell comprising the polynucleotide of claim 42 operably associated with a heterologous regulatory sequence.

49. A method of producing a polypeptide comprising:

- (a) culturing the host cell of claim 48 under conditions such that the polypeptide is expressed; and
- (b) recovering said polypeptide.

50. A composition comprising the isolated polynucleotide of claim 42.

51. An isolated polynucleotide comprising a nucleic acid selected from the group consisting of:

(a) a nucleic acid encoding a fragment of SEQ ID NO:2 or a fragment of a protein encoded by the cDNA contained in ATCC Deposit No. 209691 or 209641, wherein said fragment regulates the differentiation and/or proliferation of cells;

(b) a nucleic acid encoding a fragment of SEQ ID NO:2 or a fragment of a protein encoded by the cDNA contained in ATCC Deposit No. 209691 or 209641, wherein said fragment stimulates proliferation or differentiation of immune cells;

(c) a nucleic acid encoding a fragment of SEQ ID NO:2 or a fragment of a protein encoded by the cDNA contained in ATCC Deposit No. 209691 or 209641, wherein said fragment stimulates proliferation or differentiation of hematopoietic cells;

(d) a nucleic acid encoding a fragment of SEQ ID NO:2 or a fragment of a protein encoded by the cDNA contained in ATCC Deposit No. 209691 or 209641, wherein said fragment modulates hemostatic activity; and

(e) a nucleic acid encoding a fragment of SEQ ID NO:2 or a fragment of a protein encoded by the cDNA contained in ATCC Deposit No. 209691 or 209641, wherein said fragment modulates inflammation.

52. An isolated polynucleotide complementary to the polynucleotide of claim 51.

53. The isolated polynucleotide of claim 51 further comprising a heterologous polynucleotide.

54. A vector comprising the polynucleotide of claim 51.

55. A method of producing a vector comprising inserting the isolated polynucleotide of claim 51 into a vector.

56. A host cell comprising the vector of claim 51.

57. A host cell comprising the isolated polynucleotide of 51 operably associated with a heterologous regulatory sequence.

58. A method of producing a polypeptide comprising:

(a) culturing the host cell of claim 57 under conditions such that the polypeptide is expressed; and

(b) recovering said polypeptide.

59. A composition comprising the isolated polynucleotide of claim 51.--

Remarks

Claims 1-10, 12, 14-16 and 22 have been canceled, and new claims 25-59 have been added. Support for the newly added claims is found throughout the specification as filed.

Particularly, support for claims 25 to 33, and 35 can be found in the originally filed claims and the specification, for example, page 4, second full paragraph; page 7, second full paragraph; page 8, first full paragraph; page 10, lines 19-20; page 12, second full paragraph through the top of page 14; page 35, lines 9-12; and the paragraph spanning pages 74 to 75. Support for claim 34 can be found, for example, at page 16, third full paragraph. Additionally, support for claim 35 can be found, for example, on pages 11 to 12. Support for claim 36, can be found, for example, on page 4, third full paragraph. Further, support for claims 37 and 38 can be found, for example, on pages 18-22. Additionally, support for claim 39 can be found, for example, on page 7, last full paragraph; page 8 first full paragraph; and pages 18-22. Moreover, support for claim 40